Short Interest in CalciMedica, Inc. (NASDAQ:CALC) Expands By 112.3%

CalciMedica, Inc. (NASDAQ:CALC) was the recipient of a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 72,600 shares, a growth of 112.3% from the October 15th total of 34,200 shares. Based on an average daily volume of 52,900 shares, the days-to-cover ratio is currently 1.4 days. Approximately 1.4% of the company’s shares are sold short.

Insider Buying and Selling

In other news, CEO A. Rachel Leheny purchased 20,000 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The stock was bought at an average price of $3.75 per share, for a total transaction of $75,000.00. Following the completion of the purchase, the chief executive officer now directly owns 130,926 shares of the company’s stock, valued at $490,972.50. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other CalciMedica news, major shareholder Sanderling Venture Partners Vi purchased 86,867 shares of the stock in a transaction that occurred on Friday, November 1st. The stock was purchased at an average cost of $3.75 per share, with a total value of $325,751.25. Following the completion of the acquisition, the insider now directly owns 814,300 shares of the company’s stock, valued at $3,053,625. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO A. Rachel Leheny acquired 20,000 shares of the business’s stock in a transaction on Friday, November 1st. The shares were bought at an average cost of $3.75 per share, for a total transaction of $75,000.00. Following the acquisition, the chief executive officer now owns 130,926 shares of the company’s stock, valued at $490,972.50. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 312,944 shares of company stock valued at $1,172,910. 41.55% of the stock is currently owned by insiders.

Institutional Investors Weigh In On CalciMedica

A hedge fund recently raised its stake in CalciMedica stock. Atria Investments Inc boosted its stake in shares of CalciMedica, Inc. (NASDAQ:CALC) by 136.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 26,503 shares of the company’s stock after acquiring an additional 15,296 shares during the quarter. Atria Investments Inc owned about 0.25% of CalciMedica worth $117,000 as of its most recent filing with the Securities and Exchange Commission.

CalciMedica Price Performance

NASDAQ CALC traded down $0.08 on Wednesday, reaching $3.41. The stock had a trading volume of 83,812 shares, compared to its average volume of 36,555. The business’s 50-day moving average price is $4.15 and its 200 day moving average price is $4.57. CalciMedica has a 12-month low of $2.68 and a 12-month high of $8.38.

CalciMedica (NASDAQ:CALC) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.03. On average, research analysts forecast that CalciMedica will post -2.21 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reduced their price target on shares of CalciMedica from $20.00 to $16.00 and set a “buy” rating for the company in a research report on Monday, November 4th.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.